Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising prevalence of schizophrenia
4.1.1.2. Rising demand for advanced therapeutics
4.1.2. Restraints
4.1.2.1. Side effects associated with the drugs
4.1.2.2. XX
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis
6. By Drug Class
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. Typical Antipsychotics*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Atypical Antipsychotics
6.3.1. Quetiapine
6.3.2. Aripiprazole
6.3.3. Risperidone
6.3.4. Lurasidone
6.3.5. Clozapine
6.3.6. Olanzapine
6.3.7. Brexpiprazole
6.3.8. Lumateperone
6.3.9. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe

9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Bristol-Myers Squibb Company*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Otsuka Pharmaceutical Co., Ltd.
11.3. CHEPLAPHARM Arzneimittel GmbH
11.4. Johnson & Johnson Services, Inc.
11.5. Sumitomo Pharma Co., Ltd.
11.6. Novartis AG
11.7. Tasman Pharma, INC.
11.8. Intra-Cellular Therapies, Inc.
11.9. AbbVie Inc.
11.10. Alkermes, Inc.
11.11. Viatris Inc.
11.12. Vanda Pharmaceuticals Inc.
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us